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Treatment of either crude or purified preparations of the y-aminobutyrate (GABA)/benzodiazepine receptor 
complex with arginine-specific reagents resulted in a time- and concentration-dependent loss of PH]muscim- 
01 binding activity. Following exposure to either 2,3-butanedione or phenylglyoxal(<20 mM), rI-Ilmuscim- 
01 binding was inhibited by up to 80%. PH]Flunitrazepam binding was much less sensitive to the effects 
of the reagents. Scatchard analysis of the binding data indicated that treatment with butanedione resulted 
in a loss of PIIlmuscimol binding sites with little effect on binding affinity. Considerable protection against 
inactivation was provided by arginine and by the endogenous receptor ligand, GABA. These results indicate 
that arginine residues play a critical role in maintaining the GABA receptor in a conformation capable of 
ligand binding, possibly by participating in the binding site through interaction with the carboxylate moiety 
of GABA. 
GABA receptor; Benzodiazepine receptor; Arginine residue; Chemical modification 
1. INTRODUCTION 
y-Aminobutyrate (GABA) is the principal in- 
hibitory nemotransmitter in the mammalian cen- 
tral nervous system. A major class of GABA 
receptors (GABAA receptors) are associated with 
anion channels which in many cases constitute part 
of a protein complex which also possesses binding 
sites for benzodiazepines and other centrally active 
drugs [ 1,2]. Highly purified preparations of this 
receptor complex have been found, in most cases, 
to be comprised of at least two distinct polypep- 
tides [3-51, and two recent reports indicate that 
GABA- and benzodiazepine-receptor ligands 
photolabel different subunits of the receptor com- 
plex purified from bovine cerebral cortex [6,7]. 
Hotiever, little is known of the nature of the 
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amino acids which participate directly in the in- 
teraction between ligands and their binding sites. 
In view of a recent report, describing the primary 
amino acid sequence of GABAA receptor subunits 
[8], studies aimed at defining the amino acid 
residues of the polypeptides involved with ligand 
binding may help to elucidate the precise 
mechanism through which the receptor complex 
operates. A critical role for histidine residues in the 
binding of benzodiazepines has been reported [9]. 
The same report also demonstrated the ability of 
diazotized sulphanilate to eliminate low-affinity 
GABA binding sites. However, the reactivity of 
this compound is only moderately selective and the 
identity of the modified amino acids remains 
unclear. In the present study we report on the abili- 
ty of arginine-specific reagents to inactivate 
[3H]muscimol binding to the receptor complex. 
The data indicate that arginine residues may be in- 
timately involved with the binding of GABA to the 
GABAA receptor. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
[methylamine-3H]Muscimol (13 Ci/mmol) and 
[ZV-methyl-3H]flunitrazepam (85 Ci/mmol) were 
from Amersham (Bucks, England). Phenylgiyoxal 
and 2,3-butanedione were from Sigma (Dorset, 
England). The sources of materials used for recep- 
tCor _TAkhC;iilDl-l WE5t k3.S Jldl& _r>rCi,DT&Y :f$>. x31 
other chemicals were obtained from BDH (Dorset, 
England). 
2.2. Preparation of crude synaptic membranes 
and isolation of the receptor complex 
A crude preparation of synaptic membranes was 
prepared From pig cerebral cortex as in IlO] except 
that all media contained the protease inhibitors 
EDTA (1 mM), benzamidine (1 mM), phenyl- 
methanesulphonyl fluoride (0.3 mM), trypsin 
inhibitors type IIS and II-O (each 10 mg/l). Mem- 
branes were stored Frozen at -20°C For up to 2 
months. Before chemical modification and assay 
of receptor binding, the membranes were thawed, 
washed once with 20 mM potassium phosphate 
buffer (pH 7.5), 100 mM KCl, 0.1 mM EDTA 
(refeyyed fo as ‘buffel A’) and diaiysed for 20 Ts 
against 500 vol. buffer A. 
The GABA/benzodiazepine receptor complex 
was purified from a Triton X-100-extract of pig 
brain membranes by a combination of affinity 
chromatography, on Rol986/1-agarose, and ion- 
exchange chromatography as described in [5]. The 
cumcen1ration 05 ,j3H)mnstim~ tinting &es jn Yne 
isolated preparation was typically in the range of 
50-100 pmol/ml. The purified receptor complex 
was stored Frozen at -20°C for up to 1 month 
before use. 
2.3. Chemical modification with arginine reagents 
For modification with butanedione [ll], an ali- 
quot (-50~1) of purified receptor was diluted 
4-fold with 50 mM sodium borate (pH 3.2), 0.1% 
Triton X-100 containing butanedione at indicated 
concentrations. After incubation at 25°C for up to 
2 h, receptor binding activities were assayed either 
directly or, where indicated, after chromatography 
on a column of Sephadex G-25 in 50 mM sodium 
borate, 0.1% Triton X-100. Aliquots (400~1) of 
the membrane preparations (10 mg/ml) were 
treated similarly except that Triton X-100 was 
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omitted from the incubation buffer. Modification 
of the receptor complex with phenylglyoxal was 
performed as for butanedione but in 0.1 M sodium 
carbonate buffer (pH 8.0) instead of sodium 
borate. 
2.4. Binding assays 
Except where stated otherwise, ligand binding to 
&e~u?%& _rPJ~@or 6_~*~2ex .Wac .me~~& “$7 2 
polyethylenimine/filtration assay modified from 
that described in [5,12]. The purified receptor 
complex was incubated with 40 nM [3H]muscimol 
or 10 nM t3H]flunitrazepam at 0°C for 60 min. 
Other conditions were as stated [5]. Following in- 
cubation, the assay mixture was filtered on 
polyethylenimine-soaked filters [IZ]. The fibers 
were washed twice with 4 ml of 10 mM potassium 
phosphate (pH 7.5), 200 mM NaCl, 0.1 mM 
EDTA, dried and counted for radioactivity in 4 ml 
of scintillation fluid. All assays were performed in 
duplicate. Membranes (-0.5 mg protein) were in- 
cubated with 8 nM [‘Hlmuscimol or 2 nM 
[3H]flunitrazepam at 0°C for 60 min in a total 
volume of 500 ~1 buffer A. Following incubation, 
the assay mixtures were filtered and counted as 
described above. 
2.5. Sephadex G-25 chromatography 
Desalting, subsequent o the butanedione treat- 
ment, was performed by chromatography on a col- 
umn (1.3 x 8.5 cm) of Sephadex G-25 
pre-equilibrated with 50 mM sodium borate (pH 
%2>, a 3 9~ T*knJ >I -> m. The _re~&++J~~ ~PZ?~~Z?J~P.Q 
(200~1) was applied to the column and 
chromatographed at 0.15 ml/min in equilibration 
buffer. The initial 1.12 ml of eluate was discarded 
and the following 2.25 ml was retained for deter- 
mination of ligand binding activities. 
3. RESULTS AND DISCUSSION 
The binding of [3H]muscimol to crude mem- 
branes, or to purified preparations of the 
GABA/benzodiazepine receptor complex, was 
reduced substantially after treatment with the 
arginine-modifying reagent, 2,3-butanedione 
(fig.lA,B). In contrast, the binding of 
[3H]flunitrazepam was much less sensitive to the 
effects of the reagent (fig.lA,B). [3H]Muscimol 
binding to the purified receptor complex was also 
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Fig. 1. Effect of butanedione-treatment on ligand 
binding to the GABA/benzodiazepine receptor complex. 
Aliquots of membranes (A) or purified receptor complex 
(B) were incubated for 2 h in the absence or presence of 
butanedione as described in section 2. Following 
incubation, samples were assayed for [3H]muscimol (0) 
or [3H]flunitrazepam (0) binding activity. Results 
represent the mean and standard error of four 
independent experiments. Representative preparations 
of membranes or purified receptor complex for which 
specific [3H]muscimol binding activities were deter- 
mined, indicated values of approx. 1.5 pmol/mg and 
3.5 nmol/mg, respectively. Typically, the concentration 
of [3H]muscimol binding sites in the modification 
reaction mixture was -4 pmol/ml (membranes) or 
- 15 pmol/ml (purified receptor complex). 
inactivated (> 80% inhibition at 10 mM) selective- 
ly, after treatment with another arginine- 
modifying reagent, phenylglyoxal (not shown). In- 
activation of [3H]muscimol binding by butane- 
dione was both concentration- and time-dependent 
(fig.2). Incubation for 2 h in the presence of 
h 
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Fig.2. Time- and concentration-dependent inactivation 
of [‘Hlmuscimol binding activity. Binding of 
[3H]muscimol was measured after incubation of the 
purified receptor complex in the absence (0) or 
presence of 2.5 mM (A), 5 mM (A), 10 mM (0) or 
20 mM (m) butanedione. Each point represents the mean 
of three individual experiments. The standard errors for 
each point were less than 9%. 
20 mM butanedione reduced [3H]muscimol 
binding activity by up to 80%. 
The inactivation of [3H]muscimol binding was 
not reversible and binding activity could not be 
restored after removal of the reagent by gel filtra- 
tion (tables 1,2). Scatchard analysis of 
[3H]muscimol binding activity after treatment of 
Table I 
Scatchard analysis of [3H]muscimol binding following 
butanedione treatment 
Pretreatment & (nM) B,,, (Ore) 
Control 11.2 + 1.1 100 
Butanedione 8.4 k 1.6 43 f 8 
The purified receptor complex was incubated in the 
absence or presence of 20 mM butanedione for 2 h. 
Prior to the binding assays, both treated and untreated 
samples were chromatographed on Sephadex G-25 as 
described in section 2. In order to detect the maximum 
amount of bound ligand, [3H]muscimol binding was 
measured using a polyethyleneglycol-precipitation/ 
centrifugation assay [5], over a concentration range of 1 
to 100 nM. The butanedione-induced inactivation of 
binding activity determined by this procedure did not 
differ significantly from that measured by the filtration 
method. Results are the mean and standard error of four 
independent experiments 
127 
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Table 2 
Protection of [3H]muscimol binding activity from 
inactivation by butanedione 
Pretreatment [3H]Muscimol binding 
(‘J7o f unmodified control) 
Butanedione= 11.6 rf: 2.8 
+ 5 mM arginine 11.5 f 1.7 
+ 10 mM arginine 17.8 f 3.9 
+ 20 mM arginine 35.6 * 5.5 
+ 30 mM arginine 69.1 f 8.9 
+ 40 mM arginine 81.8 f 1.9 
+ 40 mM lysine 18.5 + 5.2 
Butanedioneb 18.2 +I 1.7 
+ 1 ,uM GABA 80.4 f 1.3 
a [3H]Muscimol binding activity was determined after 
incubation of the purified receptor for 2 h at 25°C 
with arginine or lysine in the presence or absence of 
20 mM butanedione 
b Aliquots of purified receptor were preincubated at 
25°C for 30 min in the absence or presence of 1 PM 
GABA. Samples from each preincubation mixture 
were then incubated for 90 min at 25°C in the absence 
or presence of 20 mM butanedione. Prior to 
determination of [3H]muscimol binding activity, all 
samples were chromatographed on Sephadex G-25 as 
described in section 2. Preincubation with GABA did 
not inhibit the binding of [3H]muscimol to unmodified 
samples; 116 (llO-125)% of control. All results 
represent the mean and standard error of three 
independent experiments 
the purified receptor with butanedione revealed 
that the loss of activity resulted principally from a 
reduction in the apparent number of binding sites, 
whereas the binding affinity, as represented by the 
Kd values, was not altered significantly (table 1). 
These data indicate that the arginine residues 
modified by butanedione play a critical role in 
maintaining the GABA receptor in a conformation 
capable of ligand binding, possibly by comprising 
part of the binding site itself. 
Butanedione has the potential for side reactions 
with a-amino groups and with the c-amino group 
of lysine although, under the conditions employed 
in these studies, its reactivity is reported to be 
directed at arginine residues specifically [l 11. The 
ability of arginine (lo-40 mM) but not lysine 
(40 mM) to protect up to 70% of [‘Hlmuscimol 
binding activity from inactivation (table 2) sug- 
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gests that it is a modification of arginine residues 
which results in loss of activity. [3H]Muscimol 
binding activity was also protected from inactiva- 
tion by preincubating the receptor complex in the 
presence of GABA prior to treatment with butane- 
dione. At a concentration of 1 PM, GABA pro- 
tected approx. 60% of the binding activity from 
inactivation (table 2). The ability of GABA to pro- 
tect [3H]muscimol binding.activity from inactiva- 
tion is consistent with the view that arginine 
residues, essential for GABA receptor binding, are 
components of the ligand binding sites. 
Radiolabelled arginine-reactive compounds may 
therefore supplement covalent labelling with 
[3H]muscimol [13] as tools for exploring the 
molecular structure of GABA-binding sites. 
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